The following information has been provided by Genentech.
“Genentech recently launched a newÂ websiteÂ GenentechHemophilia.com, dedicated to supporting the Hemophilia community. Here you can watch videos, read articles and learn how Genentech is committed to advancing all aspects of life with hemophilia A. Genentech supports the Hemophilia community through a variety of ways including a web series calledÂ Challenge Accepted. This web series shares what it means to live with a bleeding disorder. You’ll also find aÂ new videoÂ featuring Genentech’s commitment to safety and their robust process to monitor the safety of its medicines.
Genentech’s partnership with the hemophilia community began over 30 years ago*Â when we developed our first medicine to help people with hemophilia A. This partnership continues today through a lasting commitment to the hemophilia A community that goes far beyond providing medicines.
We’re committed to advancing all aspects of life with hemophilia A, starting with patient care. We strive to provideÂ Treatment for AllÂ who need it, including underserved communities around the globe.
WeÂ Connect the CommunityÂ through active engagements that help bring these individuals together to learn and grow.
WeÂ Support the PersonÂ through education, resources and tools designed to help individuals thrive throughout their treatment journey.
With your help, we will continue to deliverÂ nowÂ what the community needs next.Â That is our commitment to you.
Learn more atÂ GenentechHemophilia.com.”
*Genentech out licensed worldwide production and marketing of factor VIII.